Want to see DLHC full AI Analyst Report?
DLHC Stock Chart & Stats
$5.09
$0.02(0.39%)
At close: 4:00 PM EDT
$5.09
$0.02(0.39%)
Day’s Range― - ―
52-Week Range$4.74 - $8.10
Previous CloseN/A
Volume2.15K
Average Volume (3M)27.65K
Market Cap
$78.26M
Enterprise Value$217.00
Total Cash (Recent Filing)$235.00K
Total Debt (Recent Filing)$141.14M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Dec 07, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding14,493,035
10 Day Avg. Volume37,306
30 Day Avg. Volume27,646
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.72
Price to Sales (P/S)0.24
P/FCF Ratio3.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.00Price Target Upside37.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$228.20M
Bulls Say, Bears Say
Bulls Say
Consistent Free Cash FlowConsistent positive operating and free cash flow (~$13.9M TTM) provides durable liquidity to fund operations, invest in bidding and delivery, and support debt reduction. This cash generation cushions the business through procurement cycles and reduces reliance on new financing.
Margin ResilienceMaintaining a 9% adjusted EBITDA margin despite steep revenue declines indicates structural cost discipline and scalable delivery. This resilience supports continued profitability on awarded work, aids cash conversion, and improves the company's ability to deleverage while pursuing new federal contracts.
Improved Covenant FlexibilityThe secured credit amendment adds covenant headroom and allows certain restructuring and pro forma award income, reducing near-term refinancing risk and enabling management to focus on operational recovery rather than immediate covenant pressure during multi-quarter contract transitions.
Bears Say
Material Revenue DeclineA sharp, multi-quarter revenue contraction materially erodes scale and operating leverage. Reduced contract volumes lower margin absorption, constrain reinvestment in business development and tech, and make multi-period recovery dependent on winning recompetes and new awards amid competitive federal procurement.
Elevated LeverageSustained leverage with debt above equity limits financial flexibility and raises sensitivity to lower margins or delayed awards. Higher interest and principal amortization compete with investing in bids and delivery, increasing refinancing and covenant risks if cash flow weakens or procurement timing slips.
Procurement And Program RiskDependence on federal procurements exposes revenue timing to protests, continuing resolutions and reprioritization. Potential federal health funding shifts and award delays can leave capacity underutilized, extend recovery timelines, and pressure backlog conversion, making revenue restoration structurally uncertain.
DLH Holdings News
DLHC FAQ
What was DLH Holdings’s price range in the past 12 months?
DLH Holdings lowest stock price was $4.74 and its highest was $8.10 in the past 12 months.
What is DLH Holdings’s market cap?
DLH Holdings’s market cap is $78.26M.
When is DLH Holdings’s upcoming earnings report date?
DLH Holdings’s upcoming earnings report date is Dec 07, 2026 which is in 128 days.
How were DLH Holdings’s earnings last quarter?
DLH Holdings released its earnings results on Jul 29, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.99.
Is DLH Holdings overvalued?
According to Wall Street analysts DLH Holdings’s price is currently Undervalued.
Does DLH Holdings pay dividends?
DLH Holdings does not currently pay dividends.
What is DLH Holdings’s EPS estimate?
DLH Holdings’s EPS estimate is -0.16.
How many shares outstanding does DLH Holdings have?
DLH Holdings has 14,493,035 shares outstanding.
What happened to DLH Holdings’s price movement after its last earnings report?
DLH Holdings reported an EPS of -$1.16 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -9.259%.
Which hedge fund is a major shareholder of DLH Holdings?
Currently, no hedge funds are holding shares in DLHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DLH Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (37.52% Upside)
$7.00 (37.52% Upside)
Insider Transactions
Bought Shares
Worth $966.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.75%
Trailing 12-Months
Company Description
DLH Holdings
DLH Holdings Corp., headquartered in Atlanta, Georgia, was established in 1969 and operated as TeamStaff, Inc. until its name change in June 2012. The company specializes in offering a range of technology-enabled business process outsourcing, comprehensive program management solutions, and public health research and analytics services throughout the United States, with a primary focus on the federal health services market. A significant portion of DLH's work involves defense and veterans' health, where it delivers integrated healthcare, technology, and logistical support. Key clients in this sector include the Department of Veterans Affairs (VA), the Defense Health Agency, the Tele-medicine and Advanced Technology Research Center, the Navy Bureau of Medicine and Surgery, and the Army Medical Research and Material Command. Additionally, the company provides diverse human services and solutions, covering areas such as rigorous monitoring and evaluation, efficient electronic medical records migration, robust data collection and management, and thorough nutritional and social health assessments. It also offers expert IT system architecture design, strategic migration planning, and continuous maintenance services. In the sphere of public health and life sciences, DLH undertakes crucial initiatives like clinical trials, epidemiological studies, and disease prevention. It actively promotes health among underserved and at-risk communities through the creation of impactful strategic communication campaigns, research into emerging health trends, in-depth health informatics analyses, and the application of proven best practices.
DLHC Company Deck
DLHC Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated a mixed picture: material near-term financial headwinds with a steep year-over-year revenue decline (~33.5%) and a sharp drop in adjusted EBITDA (~43.6%), largely driven by program transitions to small business set-asides and contract completions. Offsetting these negatives, management reported margin resilience (9% adjusted EBITDA margin), positive free cash flow (~$3.8M), resumed deleveraging (debt reduced to $132.7M), a two-year NIH contract extension adding revenue visibility, recognition for technology capabilities, and an improving pipeline as delayed procurements return to market. Risks remain around federal health reprioritization and typical government procurement timing uncertainty, but the company appears to be stabilizing its cost structure and positioning for upcoming opportunities.View all DLHC earnings summariesDLHC Stock 12 Month Forecast
Average Price Target
$7.00
▲(37.52% Upside)
Technical Analysis
Ownership Overview
36.83% Insiders
7.37% Mutual Funds
0.25% Other Institutional Investors
51.65% Public Companies and
Individual Investors